摘要
Targeting the untargetable KRAS in cancer therapy Pingyu Liu a,Yijun Wang a,Xin Li b a Pharmacy Department,the Second Affiliated Hospital of Nanjing Medical University,Nanjing 210011,China b Department of Clinical Pharmacy,School of Pharmacy,Nanjing Medical University,Nanjing 211166,China Continuous efforts in the past three decades failed to develop approved therapies for KRAS mutant cancer.Encouragingly,recent progress in the development of KRAS inhibitors either directly towards mutant KRAS or against the crucial steps required for KRAS activation may bring breakthrough for this long-pursued undruggable target.
出处
《药学学报》
CAS
CSCD
北大核心
2019年第10期1881-1886,共6页
Acta Pharmaceutica Sinica
